Molecular Engineering III: Fc Engineering

Handbook of Therapeutic Antibodies

Volumn 1, Issue , 2008, Pages 171-196

  Peipp, Matthias ^a   Beyer, Thomas ^a   Dechant, Michael ^a   Valerius, Thomas ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Activation; Antigen; Immunogenicity; Mechanisms; Therapy

Indexed keywords

EID: 84889320899     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch8     Document Type: Chapter

References (106)

1. Aalberse, R.C., Schuurman, J. (2002) IgG4 breaking the rules. Immunology 105: 9-19.
2. Angal, S., King, D.J., Bodmer, M.W., Turner, A., Lawson, A.D., Roberts, G., Pedley, B., Adair, J.R. (1993) A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 30: 105-108.
3. Barbin, K., Stieglmaier, J., Saul, D., Stieglmaier, K., Stockmeyer, B., Pfeiffer, M., Lang, P., Fey, G.H. (2006) Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies. J Immunother 29: 122-133.
4. Berinstein, N.L., Grillo-Lopez, A.J., White, C.A., Bence-Bruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., Shen, D. (1998) Association of serum rituximab (IDECC2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9: 995-1001.
5. Bindon, C.I., Hale, G., Bruggemann, M., Waldmann, H. (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168: 127-142.
6. Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S.D., Clark, M., Waldmann, H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23: 403-411.
7. Bruggemann, M., Williams, G.T., Bindon, C. I., Clark, M.R., Walker, M.R., Jefferis, R., Waldmann, H., Neuberger, M.S. (1987) Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166: 1351-1361.
8. Burmeister, W.P., Huber, A.H., Bjorkman, P.J. (1994) Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 372: 379-383.
9. Burton, D.R. (1985) Immunoglobulin G: functional sites. Mol Immunol 22: 161-206.
10. Carpenter, P.A., Appelbaum, F.R., Corey, L., Deeg, H.J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J., Slattery, J., Levitt, D., Storb, R., Woolfrey, A., Anasetti, C. (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99: 2712-2719.
11. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
12. Chatenoud, L. (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3: 123-132.
13. Chatenoud, L. (2005) CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol 17: 632-637.
14. Clark, M.R. (1997) IgG effector mechanisms. Chem Immunol 65: 88-110.
15. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., Ravetch, J.V. (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci USA 95: 652-656.
16. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V. (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
17. Coiffier, B., Tilly, H., Pedersen, L.M., Plesner, T., Frederiksen, H., van Oers, M. H.J., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J. J., Flensburg, M.F., Petersen, J., Robak, T. (2005) HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia. Early results from an ongoing phase i/ii clinical trial. Blood 160: 448A.
18. Cole, M.S., Anasetti, C., Tso, J.Y. (1997) Human IgG2 variants of chimeric antiCD3 are nonmitogenic to T cells. J Immunol 159: 3613-3621.
19. Cragg, M.S., Glennie, M.J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103: 2738-2743.
20. Dall'Acqua, W.F., Woods, R.M., Ward, E.S., Palaszynski, S.R., Patel, N.K., Brewah, Y. A., Wu, H., Kiener, P.A., Langermann, S. (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169: 5171-5180.
21. Damle, N.K., Frost, P. (2003) Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol 3: 386-390.
22. Davies, J., Jiang, L., Pan, L.Z., LaBarre, M.J., Anderson, D., Reff, M. (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol Bioeng 74: 288-294.
23. de Lange, G.G. (1989) Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp Clin Immunogenet 6: 7-17.
24. Dechant, M., Valerius, T. (2001) IgA antibodies for cancer therapy. Crit Rev Oncol Hematol 39: 69-77.
25. Dechant, M., Vidarsson, G., Stockmeyer, B., Repp, R., Glennie, M.J., Gramatzki, M., van De Winkel, J.G., Valerius, T. (2002) Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100: 4574-4580.
26. Di Carlo, E., Forni, G., Lollini, P., Colombo, M.P., Modesti, A., Musiani, P. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97: 339-345.
27. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., Golay, J. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587.
28. Duncan, A.R., Winter, G. (1988) The binding site for C1q on IgG. Nature 332: 738-740.
29. Dyer, M.J., Hale, G., Hayhoe, F.G., Waldmann, H. (1989) Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431-1439.
30. Dyer, M.J.S., Moser, S., Brünker, P., Bird, P., Almond, N., Püentener, U., Wheat, L.M.W., Bolam, E., Berrie, E., Grau, R., Buckby, E., Kennedy, B., Stebbings, R., Hale, G., Umana, P. (2005) Enhanced potency of glycoengineered anti-CD52 monoclonal antibodies (MAbs). Blood 160: 2958A.
31. Farag, S.S., Flinn, I.W., Modali, R., Lehman, T.A., Young, D., Byrd, J.C. (2004) Fcγ RIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103: 1472-1474.
32. Ferrara, C., Stuart, F., Sondermann, P., Brunker, P., Umana, P. (2005) The carbohydrate at FcγRIIIa ASN162: An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281: 5032-5036.
33. Ferrara, C., Brunker, P., Suter, T., Moser, S., Puntener, U., Umana, P. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1: 4-N acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng 93: 851-861.
34. Friend, P.J., Hale, G., Chatenoud, L., Rebello, P., Bradley, J., Thiru, S., Phillips, J.M., Waldmann, H. (1999) Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 68: 1632-1637.
35. Ghetie, V., Ward, E.S. (2000) Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18: 739-766.
36. Glennie, M.J., van de Winkel, J.G. (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8: 503-510.
37. Herold, K.C., Hagopian, W., Auger, J.A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S.E., Harlan, D.M., Xu, D., Zivin, R.A., Bluestone, J.A. (2002) AntiCD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692-1698.
38. Hinton, P.R., Johlfs, M.G., Xiong, J.M., Hanestad, K., Ong, K.C., Bullock, C., Keller, S., Tang, M.T., Tso, J.Y., Vasquez, M., Tsurushita, N. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279: 6213-6216.
39. Hinton, P.R., Xiong, J.M., Johlfs, M.G., Tang, M.T., Keller, S., Tsurushita, N. (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176: 346-356.
40. Hirsch, F.R., Bunn, P.A., Jr. (2005) Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? J Clin Oncol 23: 9044-9047.
41. Huls, G., Heijnen, I.A., Cuomo, E., van der Linden, J., Boel, E., van de Winkel, J.G., Logtenberg, T. (1999) Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. Cancer Res 59: 5778-5784.
42. Idusogie, E.E., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Wong, P.Y., Ultsch, M., Meng, Y.G., Mulkerrin, M.G. (2000) Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 164: 4178-4184.
43. Idusogie, E.E., Wong, P.Y., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., Mulkerrin, M.G. (2001) Engineered antibodies with increased activity to recruit complement. J Immunol 166: 2571-2575.
44. Janakiraman, N., McLaughlin, P., White, C. A., Maloney, D.G., Shen, D., Grillo-Lopez, A.J. (1998) Rituximab: correlation between effector cells and clinical activity in NHL. Blood 92: 337A.
45. Jefferis, R. (1986) Polyclonal and monoclonal antibody reagents specific for IgG subclasses. Monogr Allergy 19: 71-85.
46. Jefferis, R. (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 21: 11-16.
47. Jefferis, R., Lund, J. (2002) Interaction sites on human IgG-Fc for FcγR: current models. Immunol Lett 82: 57-65.
48. Jefferis, R., Lund, J., Goodall, M. (1995) Recognition sites on human IgG for Fcγ receptors: the role of glycosylation. Immunol Lett 44: 111-117.
49. Kennedy, A.D., Beum, P.V., Solga, M.D., DiLillo, D.J., Lindorfer, M.A., Hess, C.E., Densmore, J.J., Williams, M.E., Taylor, R.P. (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172: 3280-3288.
50. Kerr, M.A. (1990) The structure and function of human IgA. Biochem J 271: 285-296.
51. Keymeulen, B., Vandemeulebroucke, E., Ziegler, A.G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., Schandene, L., Crenier, L., De Block, C., Seigneurin, J.M., De Pauw, P., Pierard, D., Weets, I., Rebello, P., Bird, P., Berrie, E., Frewin, M., Waldmann, H., Bach, J.F., Pipeleers, D., Chatenoud, L. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608.
52. Krapp, S., Mimura, Y., Jefferis, R., Huber, R., Sondermann, P. (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325: 979-989.
53. Kumpel, B.M., Wang, Y., Griffiths, H.L., Hadley, A.G., Rook, G.A. (1995) The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment. Hum Antibodies Hybridomas 6: 82-88.
54. Lammerts van Bueren, J.J., Bleeker, W.K., Bøgh, H.O., Houtkamp, M., Schuurman, J., van de Winkel, J.G.J., Parren, P.W.H.I. (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66: 7630-7638.
55. Lazar, G.A., Dang, W., Karki, S., Vafa, O., Peng, J.S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S.C., Vielmetter, J., Carmichael, D.F., Hayes, R.J., Dahiyat, B.I. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005-4010.
56. Lifely, M.R., Hale, C., Boyce, S., Keen, M.J., Phillips, J. (1995) Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5: 813-822.
57. Lin, T.S., Flinn, I.W., Modali, R., Lehman, T. A., Webb, J., Waymer, S., Moran, M.E., Lucas, M.S., Farag, S.S., Byrd, J.C. (2005) FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105: 289-291.
58. Lucisano Valim, Y.M., Lachmann, P.J. (1991) The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol 84: 1-8.
59. Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.P., Jacob, M.C., Sotto, J.J., Leroux, D., Bensa, J.C., Plumas, J. (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101: 949-954.
60. Michaelsen, T.E., Garred, P., Aase, A. (1991) Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 21: 11-16.
61. Monteiro, R.C., van de Winkel, J.G. (2003) IgA Fc receptors. Annu Rev Immunol 21: 177-204.
62. Mori, K., Kuni-Kamochi, R., Yamane-Ohnuki, N., Wakitani, M., Yamano, K., Imai, H., Kanda, Y., Niwa, R., Iida, S., Uchida, K., Shitara, K., Satoh, M. (2004) Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 88: 901-908.
63. Nimmerjahn, F., Ravetch, J.V. (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
64. Nimmerjahn, F., Ravetch, J.V. (2006) Fcγ receptors: old friends and new family members. Immunity 24: 19-28.
65. Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., Shitara, K. (2004) Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcγRIIIa functional polymorphism. Clin Cancer Res 10: 6248-6255.
66. Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., Shitara, K. (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 306: 151-160.
67. Norman, D.J., Vincenti, F., de Mattos, A.M., Barry, J.M., Levitt, D.J., Wedel, N.I., Maia, M., Light, S.E. (2000) Phase I trial of HuM291: a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70: 1707-1712.
68. Nose, M., Wigzell, H. (1983) Biological significance of carbohydrate chains on monoclonal antibodies. Proc Natl Acad Sci USA 80: 6632-6636.
69. Parren, P.W., Warmerdam, P.A., Boeije, L.C., Arts, J., Westerdaal, N.A., Vlug, A., Capel, P.J., Aarden, L.A., van de Winkel, J.G. (1992) On the interaction of IgG subclasses with the low affinity FcγRIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 90: 1537-1546.
70. Pasquier, B., Launay, P., Kanamaru, Y., Moura, I.C., Pfirsch, S., Ruffie, C., Henin, D., Benhamou, M., Pretolani, M., Blank, U., Monteiro, R.C. (2005) Identification of FcαRI as an inhibitory receptor that controls inflammation: dual role of FcRγ ITAM. Immunity 22: 31-42.
71. Pleass, R.J., Ogun, S.A., McGuinness, D.H., van de Winkel, J.G., Holder, A.A., Woof, J. M. (2003) Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. Blood 102: 4424-4430.
72. Rabbitts, T.H., Forster, A., Milstein, C.P. (1981) Human immunoglobulin heavy chain genes: evolutionary comparisons of Cμ, Cδ and Cγ genes and associated switch sequences. Nucleic Acids Res 9: 4509-4524.
73. Rademacher, T.W., Parekh, R.B., Dwek, R. A., Isenberg, D., Rook, G., Axford, J.S., Roitt, I. (1988) The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 10: 231-249.
74. Reddy, M.P., Kinney, C.A., Chaikin, M.A., Payne, A., Fishman-Lobell, J., Tsui, P., Dal Monte, P.R., Doyle, M.L., Brigham-Burke, M.R., Anderson, D., Reff, M., Newman, R., Hanna, N., Sweet, R.W., Truneh, A. (2000) Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J Immunol 164: 1925-1933.
75. Reichert, J.M., Rosensweig, C.J., Faden, L. B., Dewitz, M.C. (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078.
76. Riechmann, L., Clark, M., Waldmann, H., Winter, G. (1988) Reshaping human antibodies for therapy. Nature 332: 323-327.
77. Schachter, H. (2000) The joys of HexNAc. The synthesis and function of N-and O-glycan branches. Glycoconj J 17: 465-483.
78. Schuster, M., Umana, P., Ferrara, C., Brunker, P., Gerdes, C., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., Mudde, G.C. (2005) Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65: 7934-7941.
79. Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J.A., Presta, L.G. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 276: 6591-6604.
80. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H., Presta, L.G. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740.
81. Shih, L.B., Lu, H.H., Xuan, H., Goldenberg, D.M. (1994) Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56: 538-545.
82. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting Nacetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278: 3466-3473.
83. Sondermann, P., Huber, R., Oosthuizen, V., Jacob, U. (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 406: 267-273.
84. Stavenhagen, J., Vijh, S., Rankin, C., Gorlatov, S., Huang, L. (2004) Identification and engineering of antibodies with variant Fc regions and methods of using same US 2005/0064514 A1 MacroGenics, Inc.
85. Tao, M.H., Morrison, S.L. (1989) Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143: 2595-2601.
86. Treon, S.P., Hansen, M., Branagan, A.R., Verselis, S., Emmanouilides, C., Kimby, E., Frankel, S.R., Touroutoglou, N., Turnbull, B., Anderson, K.C., Maloney, D.G., Fox, E.A. (2005) Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 23: 474-481.
87. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 199: 1659-1669.
88. Umana, P., Jean-Mairet, J., Moudry, R., Amstutz, H., Bailey, J.E. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17: 176-180.
89. Utset, T.O., Auger, J.A., Peace, D., Zivin, R.A., Xu, D., Jolliffe, L., Alegre, M.L., Bluestone, J.A., Clark, M.R. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907-1913.
90. Valerius, T., Stockmeyer, B., van Spriel, A. B., Graziano, R.F., van den Herik-Oudijk, I.E., Repp, R., Deo, Y.M., Lund, J., Kalden, J.R., Gramatzki, M., van de Winkel, J.G. (1997) FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90: 4485-4492.
91. van de Winkel, J.G., Capel, P.J. (1993) Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14: 215-221.
92. van der Kolk, L.E., Grillo-Lopez, A.J., Baars, J.W., Hack, C.E., van Oers, M.H. (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115: 807-811.
93. van Egmond, M., van Garderen, E., van Spriel, A.B., Damen, C.A., van Amersfoort, E.S., van Zandbergen, G., van Hattum, J., Kuiper, J., van de Winkel, J.G. (2000) FcαRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med 6: 680-685.
94. van Loghem, E. (1986) Allotypic markers. Monogr Allergy 19: 40-51.
95. van Sorge, N.M., van der Pol, W.L., van de Winkel, J.G. (2003) FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61: 189-202.
96. van Spriel, A.B., van den Herik-Oudijk, I.E., van Sorge, N.M., Vile, H.A., van Strijp, J. A., van de Winkel, J.G. (1999) Effective phagocytosis and killing of Candida albicans via targeting FcγRI (CD64) or FcαRI (CD89) on neutrophils. J Infect Dis 179: 661-669.
97. Vidarsson, G., van Der Pol, W.L., van Den Elsen, J.M., Vile, H., Jansen, M., Duijs, J., Morton, H.C., Boel, E., Daha, M.R., Corthesy, B., van De Winkel, J.G. (2001) Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 166: 6250-6256.
98. Waldmann, T.A., Strober, W. (1969) Metabolism of immunoglobulins. Prog Allergy 13: 1-110.
99. Weng, W.K., Levy, R. (2001) Expression of complement inhibitors CD46: CD55: and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 98: 1352-1357.
100. Weng, W.K., Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947.
101. Woodle, E.S., Xu, D., Zivin, R.A., Auger, J., Charette, J., O'Laughlin, R., Peace, D., Jollife, L.K., Haverty, T., Bluestone, J.A., Thistlethwaite, J.R., Jr. (1999) Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68: 608-616.
102. Woof, J.M. (2005) Immunology. Tipping the scales toward more effective antibodies. Science 310: 1442-1443.
103. Woof, J.M., Mestecky, J. (2005) Mucosal immunoglobulins. Immunol Rev 206: 64-82.
104. Wright, A., Morrison, S.L. (1997) Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol 15: 26-32.
105. Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., Shitara, K., Satoh, M. (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 87: 614-622.
106. Yoo, E.M., Morrison, S.L. (2005) IgA: an immune glycoprotein. Clin Immunol 116: 3-10.